The indication
every clinic asks about.
Patients no longer ask for the product — they ask for the outcome. "Make my skin look better." Skin quality is the umbrella indication that drives the most consult bookings in the modern Australian aesthetic clinic, and polynucleotide-based protocols are the most credible answer.
“I don't want to look done. I just want my skin to look like my own — but better.”
Mode-of-action,
explained simply.
Long-chain salmon polynucleotide at 30 mg/mL applied as a topical adjunct during in-clinic skin needling — driving the active through microchannels into the dermis. The protocol pattern that built the PN category in Seoul.
Polynucleotide combined with cross-stabilised hyaluronic acid as a hybrid topical serum — paired with skin needling for immediate hydration and visible glow on top of long-term quality.
An IPL skin-rejuvenation pass at 560 nm pairs well with PN protocols — improving surface tone, reducing fine pigment and adding visible polish between needling sessions.
A treatment journey
that scales with the patient.
Each Power to Practice indication ships with a written, editable protocol — built around realistic patient outcomes and the operator workflow of an Australian aesthetic clinic.
- 01Consult & baseline imaging
Skin analysis, Fitzpatrick typing, baseline photography under consistent lighting. Establish realistic expectations and confirm protocol suitability.
- 02Session 1 — needling + PN 30
In-clinic skin needling pass with MonaLisa PN 30 applied topically during and after the pass. Patient leaves with a clear at-home regimen and a date booked for session 2.
- 03Session 2 — needling + PN 30 (week 3)
Second needling-with-PN session at 2–3 week interval. Photographic check-in. Treatment adjustments based on response.
- 04Session 3 — needling + PN or PH (week 6)
Final session of the foundation protocol. Decision point: continue with PN as quarterly maintenance, or transition to PH for hydration-led top-ups.
- 05Maintenance & top-up
Quarterly maintenance booking — single-serum needling session with PN or PH. Patient is now on the long-term skin-quality program.
Run this indication on the platforms we already support.
The numbers your finance person cares about.
Indicative figures based on Australian aesthetic clinic averages. Speak to our team for a tailored revenue and capex model for your specific patient base and treatment menu.
Common questions from clinics.
How does MonaLisa PN 30 fit into a skin-needling session?
PN 30 is designed as a topical adjunct to in-clinic skin needling. The serum is applied during or immediately after the needling pass, so the long-chain polynucleotide reaches the dermis through the microchannels created by the needling device. This is the protocol pattern that built the PN category in Seoul — your operators apply it the same way.
How is PN different from PDRN?
PDRN is a fragmented, lower-molecular-weight breakdown product. PN is the intact, long-chain form. MonaLisa PN 30 uses long-chain PN at a published concentration of 30 mg/mL — most market alternatives are blended or use the lower-cost PDRN form.
What's the typical patient profile?
Patients aged 30–55 who want visible improvement in skin quality but prefer a non-toxin, non-filler approach — or want to layer PN with their existing protocols. Strong fit for the patient who self-identifies as 'natural results only'.
Do I need additional training to run the PN protocol?
Power to Practice provides on-boarding training with every stockist agreement. The topical-with-needling application is well within the scope of any clinic already running skin-needling protocols.